Valuation -- 6/10
BUD trades at a premium to global brewer peers on both P/E and EV/EBITDA, justified by its
unmatched scale, brand portfolio, and emerging-market growth optionality. The forward P/E of
~16x on 2026E EPS of ~$4.30 is not demanding for a consumer staple compounder, but leaves
limited room for earnings misses. Consensus target of $92 implies 29% upside. The catalyst
calendar is genuinely strong (FIFA World Cup, premiumization, deleveraging), but the risk
inventory -- permanent Bud Light impairment, heavy EM/FX exposure, China weakness, tariff
uncertainty, and the emerging GLP-1 headwind -- creates a meaningful downside tail. At $71,
the risk/reward is modestly positive but not asymmetrically compelling.
Weight: 15%
Forward P/E (NTM)
~16.3x
vs HEINY ~13.6x, STZ ~11.9x
Trailing P/E
20.3x
vs HEINY ~20x, TAP ~9x
EV/EBITDA (LTM)
~12.5x
vs HEINY ~11x, TAP ~8x
Net Debt / EBITDA
2.87x
Target sub-2.5x by 2027E
Peer valuation comparison
| Company | Market Cap | Trailing P/E | Fwd P/E | EV/EBITDA | Div Yield |
|---|---|---|---|---|---|
| AB InBev (BUD) | $138.5B | 20.3x | ~16.3x | ~12.5x | 1.36% |
| Heineken (HEINY) | ~$42B | ~20.0x | ~13.6x | ~11x | ~2.1% |
| Constellation Brands (STZ) | ~$30B | ~24x | ~11.9x | ~12x | ~1.8% |
| Molson Coors (TAP) | ~$11B | ~9x | ~9x | ~8x | ~3.0% |
| Key Takeaway | BUD commands a premium to peers on scale, brand portfolio, and EM optionality. TAP is cheapest but has structural share loss. STZ forward P/E collapsed on wine/spirits writedowns. Consensus target of $92 implies 29% upside. | ||||
Peer multiples are approximate and based on consensus estimates. BUD data as of April 2026.
Data sourced from Daloopa and public filings.
Forward estimates
| Metric | 2023A | 2024A | 2025A | 2026E | 2027E |
|---|---|---|---|---|---|
| Revenue ($M) | $59,380 | $59,768 | $59,320 | ~$62,000E | ~$65,000E |
| Norm. EBITDA ($M) | $19,976 | $20,958 | $21,223 | ~$22,100-22,900E | ~$23,300-24,700E |
| EBITDA Margin | 33.6% | 35.1% | 35.8% | ~35.7-36.9%E | ~35.8-38.0%E |
| Net Income ($M) | $5,341 | $5,855 | $6,837 | ~$8,100E | ~$9,200E |
| Underlying EPS (USD) | ~$2.80 | ~$3.39 | ~$3.73 | ~$4.30E | ~$4.87E |
| Net Debt / EBITDA | ~3.0x | ~2.89x | ~2.87x | ~2.6xE | ~2.3xE |
Management guides 2026 organic EBITDA growth of 4-8%. CapEx guided to $3.5-4.0B. Normalized ETR of 26-28%.
Data sourced from Daloopa and public filings.
Key catalysts (2026-2027)
| # | Catalyst | Timeline | Magnitude | Probability |
|---|---|---|---|---|
| 1 | FIFA World Cup activation | Jun-Jul 2026 | High | High |
| 104 games across 3 North American countries; BUD is the category sponsor. Historically drives volume uplift and brand engagement. Management specifically flagged this as a major 2026 opportunity. | ||||
| 2 | Bud Light stabilization / US share gains | Ongoing 2026 | Medium-High | Medium |
| US beer business gained share in both beer and spirits in 2025. Michelob Ultra and Busch Light were top 2 volume share gainers. Bud Light recovery slow (~1.2 pp recovered) but brand is stabilizing. Super Bowl ads ranked top 10. | ||||
| 3 | Premiumization mix shift | Ongoing | Medium | High |
| Corona volumes doubled since 2018, +double digits in 30 markets. Premium beer growing >2x category rate. Mega brands now 57% of revenue, 10% CAGR since 2021. Margin-accretive. | ||||
| 4 | Continued deleveraging | 2026-2027 | Medium | High |
| Net debt/EBITDA at 2.87x, on path to sub-2.5x. No bonds maturing in 2026, 13-year weighted avg maturity, no financial covenants. Unlocks further dividend increases and buybacks ($6B program underway). | ||||
| 5 | Beyond Beer / Non-alc acceleration | 2026-2027 | Medium | High |
| Beyond Beer revenue +23% in 2025; non-alc beer +34%. Cutwater grew triple digits. Beyond Beer is 3% of revenue and growing. Management sees huge headroom. | ||||
| 6 | BEES Marketplace scaling | 2026+ | Medium | Medium |
| GMV +61% to $3.5B in 2025. Digital B2B platform is margin-accretive and creates ecosystem lock-in with retailers. Still early innings. | ||||
| 7 | China turnaround | H2 2026+ | Medium | Low-Medium |
| Q4 2025 market share stabilized. Off-trade/O2O channel pivot underway. On-trade still weak; turnaround is early and uncertain. | ||||
| 8 | Brazil volume recovery | H1 2026 | Medium | Medium-High |
| December volumes returned to growth. Premium/super premium volumes +high teens. Momentum carrying into Jan 2026. | ||||
| 9 | Progressive dividend increases | Annual | Low-Medium | High |
| 15% dividend increase in 2025. Board ambition for continued progressive dividend. Current yield ~1.4% but growing. | ||||
Key risks (bear case)
| # | Risk | Severity | Probability | Detail |
|---|---|---|---|---|
| 1 | US Bud Light permanent share loss | HIGH | Medium-High | Bud Light fell from #1 to #3 in US beer. Only ~1.2 pp of share recovered. Competitors (Modelo, Coors Light, Miller Lite) continue to gain. Brand may never fully recover its pre-boycott position. |
| 2 | FX / currency translation | HIGH | High | $1.3B adverse FX translation in 2025 (ARS, BRL, MXN). ~75% of revenue from non-USD functional currencies. ADR holders bear full currency risk. |
| 3 | Emerging market macro / political risk | MED-HIGH | Medium | ~65% of revenue from developing markets. Brazil inflation, Argentina peso, South Africa political risk, China economic slowdown all present headwinds. |
| 4 | China structural decline | MED-HIGH | Medium | Revenue declined low teens in 2025. On-trade still weak from anti-extravagance measures. Industry may be in structural decline, not just cyclical. |
| 5 | US tariffs on aluminum / beer imports | MEDIUM | Medium | 25% tariff on imported canned beer and empty cans. Aluminum at ~$4,800/MT. Scale and domestic brewing mitigate vs. smaller brewers, but COGS pressure is real. |
| 6 | GLP-1 / health and moderation trends | MEDIUM | Low-Medium | ~45% of GLP-1 patients report reduced alcohol consumption. Structural headwind to beer volumes over time. BUD better positioned via non-alc and low-cal portfolio, but risk is real and growing. |
| 7 | Volume softness / consumer trade-down | MEDIUM | Medium | Volumes were below potential in 2025. Revenue/hl +4.4% offset volume declines, but sustained volume weakness would eventually pressure the model. |
| 8 | Elevated leverage ($61B net debt) | MEDIUM | Low-Medium | Net debt still $60.9B (2.87x EBITDA). Legacy SABMiller acquisition debt. If EBITDA growth stalls, deleveraging slows. Rising rates increase refinancing cost. |
| 9 | Competitive intensity / craft and spirits | LOW-MED | Medium | Modelo Especial now #1 US beer (owned by STZ in the US). Craft and spirits continue to fragment the category. |
| 10 | Regulatory / tax risk (alcohol) | LOW-MED | Low | Potential for increased alcohol taxes, advertising restrictions, or labeling requirements. WHO guidance on alcohol harm could accelerate regulatory tightening. |
Bull and bear scenarios
Bull Case ($92+, ~16-17x 2027E EPS)
- FIFA World Cup in North America is a once-in-a-generation catalyst for the portfolio
- Premiumization + Beyond Beer + non-alc provide secular growth vectors
- Deleveraging to sub-2.5x unlocks capital return acceleration
- China turnaround would be a significant earnings inflection
- Forward P/E of ~16x on growing EPS is reasonable for a global staple compounder
Bear Case ($55-60, ~13-14x 2026E EPS)
- Bud Light recovery stalls permanently; US becomes a margin story, not a growth story
- EM currencies weaken further (BRL, MXN, ARS); reported earnings disappoint vs. organic
- China volumes continue to decline; on-trade never recovers
- GLP-1 adoption accelerates, structurally reducing alcohol occasions
- Tariff escalation or trade war disrupts supply chains and raises COGS
- Consumer recession in key markets compresses volumes and forces promotional activity
Score rationale
Score of 6/10 reflects a balanced but risk-aware setup: valuation is reasonable on forward estimates and the catalyst calendar is strong (FIFA World Cup, premiumization momentum, deleveraging), but meaningful structural and macro risks persist.
Why not higher (7-8): The risk inventory is substantial -- permanent Bud Light impairment, heavy EM/FX exposure ($1.3B adverse translation in 2025), China structural weakness, tariff uncertainty, and the emerging GLP-1 headwind all create a meaningful downside tail. The premium valuation vs. peers (16.3x forward vs. HEINY 13.6x, TAP 9x) means BUD needs to execute on growth to justify current multiples. Net debt of $60.9B (2.87x EBITDA) from the legacy SABMiller deal remains a structural constraint. A pullback toward $60-65 (14-15x forward) would shift this to a more attractive entry.
Why not lower (4-5): The catalyst calendar is genuinely strong and near-term -- FIFA World Cup sponsorship is a once-in-a-generation event for the brand portfolio. Management has executed well on margin expansion (33.6% to 35.8% EBITDA margin over 2023-2025) and capital allocation. Premiumization is working (mega brands 57% of revenue, 10% CAGR). Deleveraging is on track. Consensus target of $92 implies 29% upside. Beyond Beer and non-alc provide optionality against the GLP-1/moderation headwind.
Net assessment: At $71, the risk/reward skews modestly positive but does not offer a wide margin of safety. This is a HOLD / Watchlist position -- strong enough franchise and catalysts to monitor closely, but not enough asymmetry to build a conviction position at current levels.
Data sourced from Daloopa, company earnings transcripts, and public consensus estimates. Analysis as of April 2026.